Summary
This narrative review examines quercetin, a dietary flavonoid abundant in plant foods, as a potential pharmaceutical agent for cardiovascular disease management. The authors synthesise evidence from preclinical studies demonstrating quercetin's mechanisms of action via antioxidant and anti-inflammatory pathways, whilst critically appraising the translational gap between in vitro findings and human clinical efficacy. The review positions quercetin within the broader context of phytochemical therapeutics whilst acknowledging the need for well-designed clinical trials.
UK applicability
UK dietary recommendations and cardiovascular prevention strategies do not currently incorporate quercetin supplementation, though quercetin-rich foods (apples, berries, onions) are widely available. These findings may inform future UK nutrition policy if clinical evidence strengthens, but currently represent exploratory pharmaceutical research rather than actionable dietary guidance.
Key measures
Pharmacological mechanisms (antioxidant capacity, inflammatory markers, endothelial function); preclinical efficacy endpoints; assessment of clinical evidence gaps
Outcomes reported
The review synthesised evidence on quercetin's pharmacological mechanisms in cardiovascular disease, including antioxidant, anti-inflammatory, and endothelial protective pathways identified in preclinical studies. The authors assessed the translational potential of these mechanisms toward human clinical application.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.